Verrica Q2 net loss $13.2M; YCANTH dispensed units up 28% sequentially, 46% YoY

Verrica Pharmaceuticals Inc.

Q2 total revenue $5.9M (down from $12.7M YoY due to $8M milestone in prior year); YCANTH net product revenue $5.1M (+18.7% QoQ, +12.3% YoY).
Q2 net loss $13.2M ($0.62/share) vs net income $0.2M in Q2 2025; non-GAAP net loss $10.2M ($0.48/share).
YCANTH dispensed applicator units reached 19,626 in Q2, up 28.3% QoQ and 46.1% YoY; record quarterly demand.
Entered $27.5M credit facility with Chairman Paul B. Manning; cash runway could extend into 2028.
Phase 3 common warts topline data expected mid-2027; COVE-2 and COVE-3 trials recruiting; settled 2022 class action for $1.7M after insurance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.